Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

eople in the United States living with PHN.

HIV-DSP is caused primarily by three factors: direct activation of cells known as sensory neurons by the HIV virus, the immune system's fight against the infection, and the drugs administered to treat HIV. Painful HIV-DSP is characterized by significant pain in the feet and hands.

According to Frost & Sullivan, neuropathic pain affects approximately 15% of the HIV infected community. According to the CDC, in 2005 there were 956,000 people in the United States infected with HIV. There are currently no specific treatments approved in the United States or Europe for HIV-DSP.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including PHN, painful HIV-DSP and PDN. NeurogesX's late stage product portfolio is led by product candidate NGX-4010, a topical patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding NGX-4010 clinical trials, including the ti
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   Fruit Street Health (Fruit Street), today ... of funding. The round, which includes ... of individual investors, the majority of whom are prominent ... round are; Houston Cardiology Consultants Partner Asif Ali, ... Rapha Family Medicine Practice Owner Frances Ilozue , ...
(Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 CarePoint Health ... removal of a cancerous prostate, along with the adjacent ... new da Vinci robotic Xi platform was performed at ... performed by Dr. Mutahar Ahmed and Dr. Yale Shulman ... and anesthesiologists, specifically trained for robotic procedures. The robot ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
(Date:9/18/2014)... New research led by Queen,s University professor Robert Campbell ... surgery is not helpful or necessary., Glaucoma is the ... and about 400,000 Canadians are afflicted with the disease, ... being high enough to damage the optic nerve. The ... eye to the brain and is a vital part ...
(Date:9/18/2014)... German . In ... fight a pathogen tooth and nail, but rather tolerate it to ... of tolerance is that the disease only progresses very slowly ... pathogen load. , Roland Regoes, a senior scientist at ETH Zurich,s ... He set about investigating whether there are infected people who are ...
(Date:9/18/2014)... September 18, 2014 It is almost time ... or walk for healthier and happier kids. The South ... in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place on ... be outside of Coral Gables City Hall located at 405 ...
Breaking Medicine News(10 mins):Health News:CarePoint Health Physicians Perform the First Prostatectomy in New Jersey Using the da Vinci Xi Robot 2Health News:CarePoint Health Physicians Perform the First Prostatectomy in New Jersey Using the da Vinci Xi Robot 3Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3
... get the blues during the course of the winter and ... far more difficult to overcome the seasonal affective disorder (SAD), ... ,Those who suffer from SAD overeat, sleep ... irritability and depression and develop an aversion to social interactions. ...
... associated with several alleged miscarriages of justice has been ... decision has been hailed as one to preserve public ... officials in Saskatchewan have voted to curtail practicing privileges ... Smith. ,Smith had been granted temporary ...
... are reporting that the traditional method of assessing the ... the danger //of missing one-third of women who are ... ,Roger Blumenthal, M.D., an associate professor and ... Johns Hopkins University School of Medicine and its Heart ...
... University of Chicago have announced findings of archeological evidence that ... leading to the destruction of a city. Clemens Reichel, a ... was conducted was a war zone. Artifacts from daily life ... at the Iraqi border. ,The findings prove ...
... milk is so there is study in Australia ... with nutraceutical, pharmaceutical and agrochemical potential.// ... Queensland's Institute for Molecular Bioscience (IMB) and the ... has teamed up with MG Nutritionals for the ...
... Woo Suk the cloning pioneer of South Korea is defending ... editors of Science magazine in Washington to retract his work.//, ... magazine, Donald Kennedy said that Hwang would have 'days or ... his bid to retract a pioneering article that held out ...
Cached Medicine News:Health News:Calcium Levels Could Indicate Future Heart Disease Risk 2Health News:Excavations Reveal Clues Of Early Warfare 2Health News:Scientist Calls Upon Media To Retract His Work 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: